Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se

SATMEG trials

SATMEG has already initiated two clinical trials for metastatic UVM patients: SCANDIUM (clinical PI: co-applicant Roger Olofsson Bagge) and PEMDAC (clinical PI: co-applicant Lars Ny).


In this trial, isolated liver perfusion, a surgical oncology method is compared to best-alternative-care in a phase III academic trial. During the surgical procedure, biopsies are given to the lab so that we can analyze the tumors’ genetics and generate PDX models. Since biopsies are generally not taken from UVM patients’ liver metastases, this is a truly unique possibility.

PEMDAC trial 

In this trial, epigenetic therapy (HDAC inhibitor entinostat) is combined with immune therapy (PD1 antibody pembroluzimab). The rationale for this trial comes from pre-clinical data from the lab showing that it is possible to enhance the expression of antigen-presenting molecule HLA of uveal melanoma by HDAC inhibitors. There are also likely other mechanisms that could enhance immunity and translational efforts of this trial will elucidate mechanism of action if responses are seen.



Page Manager: Yael Zukovsky Fitoussi|Last update: 1/21/2019

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?